Title: Estrogens and Tricyclic Antidepressants for Stress Urinary Incontinence: Guidelines, Clinical and Cost-Effectiveness

Date: 13 November 2007

Research question:

1. What is the clinical benefit and harm of using estrogens for patients with stress urinary incontinence (SUI)?
2. What is the clinical benefit and harm of using tricyclic antidepressants for patients with SUI?
3. What is the cost-effectiveness of using estrogens for patients with SUI?
4. What is the cost-effectiveness of using tricyclic antidepressants for patients with SUI?
5. What are the guidelines for using estrogens for patients with SUI?
6. What are the guidelines for using tricyclic antidepressants for patients with SUI?
7. What Canadian and international advisories have been released regarding the use of estrogens with SUI?
8. What Canadian and international advisories have been released regarding the use of tricyclic antidepressants with SUI?

Methods:

A limited literature search was conducted on key health technology assessment resources, including PubMed, the Cochrane Library (Issue 4, 2007), University of York Centre for Reviews and Dissemination (CRD) databases, ECRI, EuroScan, international HTA agencies, and a focused Internet search. Results include articles published between 2002 and the present, and are limited to English language publications only. Filters were applied to limit the retrieval to HTA/systematic reviews, guidelines, economic evaluations, and randomized controlled trials. Internet links are provided, where available.

Disclaimer: The Health Technology Inquiry Service (HTIS) is an information service for those involved in planning and providing health care in Canada. HTIS responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. HTIS responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report.

Copyright: This report contains CADTH copyright material and may contain material in which a third party owns copyright. This report may be used for the purposes of research or private study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner.

Links: This report may contain links to other information on available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions.
Results:

The results are listed below and additional references of interest are included in the attached appendix. No relevant health technology assessments, economic evaluations, or advisories were identified in the literature search.

Health technology assessments

No literature identified.

Systematic reviews and meta-analyses


Economic analyses and cost information

No literature identified.

Randomized controlled trials


Guidelines and recommendations


   *Note:* See “Stress urinary incontinence” p. 35
  
Note: See Continence chapter: p. 69

  
Note: See “Urogenital Symptoms” p. 3

  
Note: See “Pharmacologic Options for Stress Incontinence” p. 7

Prepared by:

Karen Cimon, Research Assistant
Health Technology Inquiry Service
Email: htis@cadth.ca
Tel: 1-866-898-8439
Appendix – Further information:

Observational studies


Review articles


CRD abstract available: [http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12004008175](http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12004008175).


Additional references


   *Note: Stress urinary incontinence not specified with reference to possible pharmacologic management.*